Analyst Erin Wright of Morgan Stanley maintained a Buy rating on Quest Diagnostics, boosting the price target to $191.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Erin Wright has given his Buy rating due to a combination of factors that highlight Quest Diagnostics’ strong financial outlook and strategic positioning. The company has raised its 2025 earnings per share guidance, reflecting robust utilization trends and market share gains. This positive outlook is supported by an anticipated revenue growth of 9.4-10.6% in 2025, driven by both organic growth and successful cost-saving initiatives.
Furthermore, Quest Diagnostics is benefiting from expanded access through new contracts, which have significantly increased its customer base. The growth in advanced diagnostics, particularly in Alzheimer’s and cardiometabolic testing, is also contributing positively. Additionally, the company is well-positioned to navigate potential regulatory challenges, making it a relatively safe investment in the healthcare services sector. These factors, combined with productivity improvements and strong execution, underpin Erin Wright’s Buy rating for Quest Diagnostics.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $198.00 price target.